Skip to main content

Advertisement

SpringerLink
Log in

Advances in Chemotherapy for Pancreatic Cancer

  • Review Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Pancreatic cancer remains challenging to treat. Over the past decade, there have been some major improvements in systemic therapy. Gemcitabine remains the key drug for both early and advanced cancer but combination chemotherapy is emerging as a new paradigm for patients with good performance status. This review focuses on current chemotherapy status for patients with pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cameron JL, Riall TS, Coleman J, Belcher KA (2006) One thousand consecutive pancreaticoduodenectomies. Ann Surg 244:10–15. doi:10.1097/01.sla.0000217673.04165.ea

    Article  PubMed Central  PubMed  Google Scholar 

  2. Bilimoria KY, Bentrem DJ, Ko CY et al (2007) Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 110:738–744. doi:10.1002/cncr.22852

    Article  PubMed  Google Scholar 

  3. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825. doi:10.1056/NEJMoa1011923

    Article  CAS  PubMed  Google Scholar 

  4. Chua YJ, Karapetis CS, Gebski V, et al. (2014) Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin)-treated patients with metastatic pancreatic cancer: The randomized phase II PAN1 study. J. Clin. Oncol. 32: (suppl 3; abstr 228)

  5. Heestand GM, Murphy JD, Moughan J, et al. (2014) A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704. J. Clin. Oncol. 32: (suppl 3; abstr 176)

  6. Morinaga S, Nakamura Y, Katayama Y, et al. (2014) MicroRNA-21 ISH analysis to predict DFS in pancreatic cancer patients undergoing adjuvant gemcitabine after curative surgery. J. Clin. Oncol. 32: (suppl 3; abstr 234)

  7. Liao W-C, Chien K-L, Lin Y-L et al (2013) Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 14:1095–1103. doi:10.1016/S1470-2045(13)70388-7

    Article  PubMed  Google Scholar 

  8. Seufferlein T, Bachet JB, Van Cutsem E, et al. (2012) Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol ESMO 23 Suppl 7:vii33–40. doi: 10.1093/annonc/mds224

  9. Hartwig W, Strobel O, Hinz U et al (2013) CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 20:2188–2196. doi:10.1245/s10434-012-2809-1

    Article  PubMed  Google Scholar 

  10. Bold RJ (2013) Re: CA 19–9 in potentially resectable pancreatic cancer: perspective to adjust surgical and preoperative therapy. Ann Surg Oncol 20:2108–2110. doi:10.1245/s10434-012-2820-6

    Article  PubMed  Google Scholar 

  11. Valle JW, Palmer D, Jackson R et al (2014) Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. J Clin Oncol Off J Am Soc Clin Oncol 32:504–512. doi:10.1200/JCO.2013.50.7657

    Article  Google Scholar 

  12. Neoptolemos JP, Stocken DD, Tudur Smith C et al (2009) Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and −3(v1) trials. Br J Cancer 100:246–250. doi:10.1038/sj.bjc.6604838

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Oettle H, Neuhaus P, Hochhaus A et al (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA J Am Med Assoc 310:1473–1481. doi:10.1001/jama.2013.279201

    Article  CAS  Google Scholar 

  14. Fukutomi A, Uesaka K, Boku N, et al. (2013) JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol 31, 2013 (suppl; abstr 4008)

  15. Bakkevold KE, Arnesjø B, Dahl O (1990) Kambestad B (1993) Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater–results of a controlled, prospective, randomised multicentre study. Eur J Cancer Oxf Engl 29A:698–703

    Google Scholar 

  16. Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA J Am Med Assoc 304:1073–1081. doi:10.1001/jama.2010.1275

    Article  CAS  Google Scholar 

  17. Takada T, Amano H, Yasuda H et al (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685–1695. doi:10.1002/cncr.10831

    Article  PubMed  Google Scholar 

  18. Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210. doi:10.1056/NEJMoa032295

    Article  CAS  PubMed  Google Scholar 

  19. Kosuge T, Kiuchi T, Mukai K et al (2006) A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 36:159–165. doi:10.1093/jjco/hyi234

    Article  PubMed  Google Scholar 

  20. Regine WF, Winter KA, Abrams R et al (2011) Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 18:1319–1326. doi:10.1245/s10434-011-1630-6

    Article  PubMed Central  PubMed  Google Scholar 

  21. Ueno H, Kosuge T, Matsuyama Y et al (2009) A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101:908–915. doi:10.1038/sj.bjc.6605256

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Neoptolemos European Study Group for Pancreatic Cancer (ESPAC) - Trial 4: combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer. http://www.isrctn.com/ISRCTN9639743422

  23. Van Laethem J-L, Hammel P, Mornex F et al (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol Off J Am Soc Clin Oncol 28:4450–4456. doi:10.1200/JCO.2010.30.3446

    Article  Google Scholar 

  24. Butturini G, Stocken DD, Wente MN et al (1960) (2008) Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg Chic Ill 143:75–83. doi:10.1001/archsurg.2007.17, discussion 83

    Article  Google Scholar 

  25. Menon KV, Gomez D, Smith AM et al (2009) Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB 11:18–24. doi:10.1111/j.1477-2574.2008.00013.x

    Article  PubMed Central  PubMed  Google Scholar 

  26. Sanjay P, Takaori K, Govil S et al (2012) “Artery-first” approaches to pancreatoduodenectomy. Br J Surg 99:1027–1035. doi:10.1002/bjs.8763

    Article  CAS  PubMed  Google Scholar 

  27. Spitz FR, Abbruzzese JL, Lee JE et al (1997) Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol Off J Am Soc Clin Oncol 15:928–937

    CAS  Google Scholar 

  28. Heinrich S, Pestalozzi BC, Schäfer M et al (2008) Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol 26:2526–2531. doi:10.1200/JCO.2007.15.5556

    Article  CAS  Google Scholar 

  29. Palmer DH, Stocken DD, Hewitt H et al (2007) A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 14:2088–2096. doi:10.1245/s10434-007-9384-x

    Article  PubMed  Google Scholar 

  30. Shrikhande SV, Arya S, Barreto SG et al (2011) Borderline resectable pancreatic tumors: is there a need for further refinement of this stage? Hepatobiliary Pancreat Dis Int HBPD INT 10:319–324

    Article  Google Scholar 

  31. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13(8):1035–46

  32. Katz MHG, Pisters PWT, Evans DB et al (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206:833–846. doi:10.1016/j.jamcollsurg.2007.12.020, discussion 846–848

    Article  PubMed  Google Scholar 

  33. Hosein PJ, Macintyre J, Kawamura C et al (2012) A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 12:199. doi:10.1186/1471-2407-12-199

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients With Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study. https://clinicaltrials.gov/ct2/show/NCT01821612

  35. Christians KK, Tsai S, Mahmoud A et al (2014) Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm? Oncologist 19:266–274. doi:10.1634/theoncologist. 2013-0273

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Leone F, Gatti M, Massucco P et al (2013) Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer 119:277–284. doi:10.1002/cncr.27736

    Article  CAS  PubMed  Google Scholar 

  37. Takahashi H, Ohigashi H, Gotoh K et al (2013) Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg 258:1040–1050. doi:10.1097/SLA.0b013e31829b3ce4

    Article  PubMed  Google Scholar 

  38. Kim ST, Park JO, Lee J et al (2006) A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106:1339–1346. doi:10.1002/cncr.21741

    Article  CAS  PubMed  Google Scholar 

  39. Motoi F, Ishida K, Fujishima F et al (2013) Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 20:3794–3801. doi:10.1245/s10434-013-3129-9

    Article  PubMed  Google Scholar 

  40. Kharofa J, Kelly TR, Ritch PS, et al. (2012) 5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer. J Clin Oncol 30, 2012 (suppl; abstr e14613)

  41. Lee J-L, Kim SC, Kim J-H et al (2012) Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery 152:851–862. doi:10.1016/j.surg.2012.03.010

    Article  PubMed  Google Scholar 

  42. Kang CM, Chung YE, Park JY et al (2012) Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg Off J Soc Surg Aliment Tract 16:509–517. doi:10.1007/s11605-011-1784-3

    Article  Google Scholar 

  43. Chuong MD, Hayman TJ, Patel MR et al (2011) Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. Gastrointest Cancer Res GCR 4:128–134

    Google Scholar 

  44. Barugola G, Partelli S, Crippa S et al (2012) Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg 203:132–139. doi:10.1016/j.amjsurg.2011.03.008

    Article  PubMed  Google Scholar 

  45. Stokes JB, Nolan NJ, Stelow EB et al (2011) Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 18:619–627. doi:10.1245/s10434-010-1456-7

    Article  PubMed  Google Scholar 

  46. Sahora K, Kuehrer I, Schindl M et al (2011) NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg 35:1580–1589. doi:10.1007/s00268-011-1113-8

    Article  PubMed  Google Scholar 

  47. Chun YS, Milestone BN, Watson JC et al (2010) Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol 17:2832–2838. doi:10.1245/s10434-010-1284-9

    Article  PubMed  Google Scholar 

  48. McClaine RJ, Lowy AM, Sussman JJ et al (2010) Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB 12:73–79. doi:10.1111/j.1477-2574.2009.00136.x

    Article  PubMed Central  PubMed  Google Scholar 

  49. Evans DB, Varadhachary GR, Crane CH et al (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol 26:3496–3502. doi:10.1200/JCO.2007.15.8634

    Article  CAS  Google Scholar 

  50. Varadhachary GR, Wolff RA, Crane CH et al (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol 26:3487–3495. doi:10.1200/JCO.2007.15.8642

    Article  CAS  Google Scholar 

  51. Faris JE, Wo JY (2013) The controversial role of chemoradiation for patients with locally advanced pancreatic cancer. Oncologist 18:981–985. doi:10.1634/theoncologist. 2013-0270

    Article  PubMed Central  PubMed  Google Scholar 

  52. Mukherjee S, Hurt CN, Bridgewater J et al (2013) Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 14:317–326. doi:10.1016/S1470-2045(13)70021-4

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Huguet F, André T, Hammel P et al (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol Off J Am Soc Clin Oncol 25:326–331. doi:10.1200/JCO.2006.07.5663

    Article  CAS  Google Scholar 

  54. Loehrer PJ Sr, Feng Y, Cardenes H et al (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol Off J Am Soc Clin Oncol 29:4105–4112. doi:10.1200/JCO.2011.34.8904

    Article  CAS  Google Scholar 

  55. Hammel P, Huguet F, Laethem J-LV, et al. (2013) Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. J Clin Oncol 31, 2013 (suppl; abstr LBA4003)

  56. Hazel JJ, Thirlwell MP, Huggins M et al (1981) Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol 32:164–165

    CAS  PubMed  Google Scholar 

  57. Klaassen DJ, MacIntyre JM, Catton GE et al (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil–an Eastern Cooperative Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol 3:373–378

    CAS  Google Scholar 

  58. Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 80:751–755.

  59. Chauffert B, Mornex F, Bonnetain F et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol Off J Eur Soc Med Oncol ESMO 19:1592–1599. doi:10.1093/annonc/mdn281

    Article  CAS  Google Scholar 

  60. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol Off J Am Soc Clin Oncol 15:2403–2413

    CAS  Google Scholar 

  61. Goldstein D, Maraghi RHE, Hammel P, et al. (2014) Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. J Clin Oncol 32, 2014 (suppl 3; abstr 178)

  62. Von Hoff DD, Ramanathan RK, Borad MJ et al (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol Off J Am Soc Clin Oncol 29:4548–4554. doi:10.1200/JCO.2011.36.5742

    Article  Google Scholar 

  63. Herrmann R, Bodoky G, Ruhstaller T et al (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol 25:2212–2217. doi:10.1200/JCO.2006.09.0886

    Article  CAS  Google Scholar 

  64. Poplin E, Feng Y, Berlin J et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol 27:3778–3785. doi:10.1200/JCO.2008.20.9007

    Article  CAS  Google Scholar 

  65. Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 23:3509–3516. doi:10.1200/JCO.2005.06.023

    Article  CAS  Google Scholar 

  66. Colucci G, Labianca R, Di Costanzo F et al (2010) Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol Off J Am Soc Clin Oncol 28:1645–1651. doi:10.1200/JCO.2009.25.4433

    Article  CAS  Google Scholar 

  67. Stathopoulos GP, Syrigos K, Aravantinos G et al (2006) A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95:587–592. doi:10.1038/sj.bjc.6603301

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. Schneider BP, Ganjoo KN, Seitz DE et al (2003) Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 65:218–223

    Article  CAS  PubMed  Google Scholar 

  69. Cunningham D, Chau I, Stocken DD et al (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol 27:5513–5518. doi:10.1200/JCO.2009.24.2446

    Article  CAS  Google Scholar 

  70. Heinemann V, Boeck S, Hinke A et al (2008) Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8:82. doi:10.1186/1471-2407-8-82

    Article  PubMed Central  PubMed  Google Scholar 

  71. Bayraktar S, Rocha-Lima CM (2010) Advanced or metastatic pancreatic cancer: molecular targeted therapies. Mt Sinai J Med N Y 77:606–619. doi:10.1002/msj.20217

    Article  Google Scholar 

  72. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol Off J Am Soc Clin Oncol 25:1960–1966. doi:10.1200/JCO.2006.07.9525

    Article  CAS  Google Scholar 

  73. James ES, Yao X, Cong X, et al. (2014) Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). J Clin Oncol 32, 2014 (suppl; abstr e15226)

  74. Yardley DA (2013) nab-Paclitaxel mechanisms of action and delivery. J Control Release Off J Control Release Soc 170:365–372. doi:10.1016/j.jconrel.2013.05.041

    Article  CAS  Google Scholar 

  75. Bramhall SR, Schulz J, Nemunaitis J et al (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167. doi:10.1038/sj.bjc.6600446

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  76. Ueno H, Ioka T, Ikeda M et al (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol Off J Am Soc Clin Oncol 31:1640–1648. doi:10.1200/JCO.2012.43.3680

    Article  CAS  Google Scholar 

  77. Pelzer U, Schwaner I, Stieler J et al (1990) (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer Oxf Engl 47:1676–1681. doi:10.1016/j.ejca.2011.04.011

    Article  Google Scholar 

  78. Takamori H, Hiraoka T, Kanemitsu K et al (1994) Treatment strategies for hepatic metastases from pancreatic cancer in patients previously treated with radical resection combined with intraoperative radiation therapy. HPB Surg World J Hepatic Pancreat Biliary Surg 8:107–110

    Article  CAS  Google Scholar 

  79. Klempnauer J, Ridder GJ, Piso P, Pichlmayr R (1996) Is liver resection in metastases of exocrine pancreatic carcinoma justified? Chir Z Für Alle Geb Oper Medizen 67:366–370

    CAS  Google Scholar 

  80. Shimada K, Kosuge T, Yamamoto J et al (2004) Successful outcome after resection of pancreatic cancer with a solitary hepatic metastasis. Hepatogastroenterology 51:603–605

    PubMed  Google Scholar 

  81. Yamada H, Hirano S, Tanaka E et al (2006) Surgical treatment of liver metastases from pancreatic cancer. HPB 8:85–88. doi:10.1080/13651820500472200

    Article  PubMed Central  PubMed  Google Scholar 

  82. Shrikhande SV, Kleeff J, Reiser C et al (2007) Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 14:118–127. doi:10.1245/s10434-006-9131-8

    Article  PubMed  Google Scholar 

  83. Yamada S, Fujii T, Sugimoto H et al (2009) Pancreatic cancer with distant metastases: a contraindication for radical surgery? Hepatogastroenterology 56:881–885

    PubMed  Google Scholar 

  84. Yamada S, Nakao A, Fujii T et al (2009) Pancreatic cancer with paraaortic lymph node metastasis: a contraindication for radical surgery? Pancreas 38:e13–17. doi:10.1097/MPA.0b013e3181889e2d

    Article  PubMed  Google Scholar 

  85. Michalski CW, Erkan M, Hüser N et al (2008) Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig Surg 25:473–480. doi:10.1159/000184739

    Article  PubMed  Google Scholar 

  86. Iacobuzio-Donahue CA, Fu B, Yachida S et al (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol 27:1806–1813. doi:10.1200/JCO.2008.17.7188

    Article  CAS  Google Scholar 

  87. Crane CH, Varadhachary GR, Yordy JS et al (2011) Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol Off J Am Soc Clin Oncol 29:3037–3043. doi:10.1200/JCO.2010.33.8038

    Article  CAS  Google Scholar 

  88. Boone BA, Sabbaghian S, Zenati M et al (2014) Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer. J Surg Oncol. doi:10.1002/jso.23606

    PubMed  Google Scholar 

  89. Le DT, Wang-Gillam A, Picozzi V, et al. (2014) A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results. J Clin Oncol 32, 2014 (suppl 3; abstr 177)

  90. Jesus-Acosta AD, O’Dwyer PJ, Ramanathan RK, et al. (2014) A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA). J Clin Oncol 32, 2014 (suppl 3; abstr 257)

  91. Gracian AC, Jameson MB, Grande E, et al. (2014) A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer. J Clin Oncol 32, 2014 (suppl 3; abstr 279)

  92. Thota R, Goff LW, Chan E, et al. (2014) A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC). J Clin Oncol 32, 2014 (suppl 3; abstr 297)

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Mazumdar Shaw Cancer Centre, Narayana Health, Bangalore, India

    Bhawna Sirohi

  2. Dubai Hospital, Dubai, UAE

    Shaheenah Dawood

  3. Department of GI and HPB Surgery, Tata Memorial Centre, Mumbai, India

    Shailesh V. Shrikhande

  4. Department of Medical Oncology, CMC, Vellore, India

    Ashish Singh

Authors
  1. Bhawna Sirohi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashish Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shaheenah Dawood
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shailesh V. Shrikhande
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bhawna Sirohi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sirohi, B., Singh, A., Dawood, S. et al. Advances in Chemotherapy for Pancreatic Cancer. Indian J Surg Oncol 6, 47–56 (2015). https://doi.org/10.1007/s13193-014-0371-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-014-0371-y

Keywords

Search

Navigation